(51) International Patent Classification 5:
C07C 259/06, C07D 207/38, 207/06
C07K 5/06, A61K 31/16, 31/40
A61K 37/64

(11) International Publication Number:
WO 91/02716

(43) International Publication Date:
7 March 1991 (07.03.91)

(21) International Application Number:
PCT/GB90/01117

(22) International Filing Date:
20 July 1990 (20.07.90)

(30) Priority data:
8919251.2 24 August 1989 (24.08.89) GB

(71) Applicant (for all designated States except US):
BRITISH BIO-TECHNOLOGY LIMITED [GB/GB]; Watlington Road, Cowley, Oxford OX4 5LY (GB).

(71) Applicant (for US only):
CAMPION, Colin [GB/GB]; 3 Howe Close, Wheatley, Oxon OX9 1SS (GB).
DAVIDSON, Alan, Hornsby [GB/GB]; 27 Newland Mill, Winsey, Oxon OX8 6HH (GB).
DICKENS, Jonathan, Philip [GB/GB]; Burton House, Park Farm Road, High Wycombe, Bucks HP12 4AF (GB).
CRIMMIN, Michael, John [GB/GB]; Oaklea, 64 Fernbank Road, Ascot SL5 8HE (GB).

(74) Agents: SHEARD, Andrew, Gregory et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US.

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS

(57) Abstract

Compounds of general formula (I) wherein R1 represents a hydrogen atom or a C1-C6 alkyl, C1-C6 alkynyl, phenyl, phenyl(C1-C6)alkyl, C6-C10 alkylalkylmethyl, phenylalkyloxyalkylmethyl, substituted phenylalkyloxyalkylmethyl, phenyl(C1-C6)alkylalkyloxyalkylmethyl or heterocyclylalkyloxyalkylmethyl group; or R1 represents -S-Rx wherein Rx represents a group a; R2 represents a hydrogen atom or a C1-C6 alkyl, C1-C6 alkenyl, phenylalkyloxyalkylmethyl, cycloalkylalkylalkyloxyalkylmethyl or cycloalkenylalkyloxyalkylmethyl; R3 represents an amino acid side chain or a C1-C6 alkyl, benzyl, (C1-C6)alkoxybenzyl, benzyloxy(C1-C6)alkyl or benzyloxybenzyl group; R4 represents a hydrogen atom or a methyl group; R5 represents a group (CH2)nA; or R4 and R5 together represent a group β; Q represents CH2 or CO; m is an integer from 1 to 3; n is an integer from 1 to 6; and A represents a hydroxy, (C1-C6)alkoxy, (C2-C5)acyloxy, (C1-C6)alkylthio, phenylthio, (C2-C5)acylamino or N-pyrrolidone group or a salt and/or N-oxide and/or (where the compound is a thio-compound) a sulfoxide or sulphone thereof have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumour invasion.

* See back of page
Hydroxamic acid based collagenase inhibitors

COMPAGNIES

This invention relates to pharmaceutically and
veterinarily active compounds, which are derivatives of
hydroxamic acid.

The compounds of the present invention act as
inhibitors of metalloproteases involved in tissue
degradation, such as collagenase, which initiates
collagen breakdown, stromelysin (protoplasmase),
gelatinase and collagenase (IV). There is evidence
implicating collagenase as one of the key enzymes in
the breakdown of articular cartilage and bone in
rheumatoid arthritis (Arthritis and Rheumatism, 20,
1231 - 1239, 1977). Potent inhibitors of collagenase
and other metalloproteases involved in tissue
degradation are useful in the treatment of rheumatoid
arthritis and related diseases in which collagenolytic
activity is important. Inhibitors of metalloproteases
of this type can therefore be used in treating or
preventing conditions which involve tissue breakdown;
they are therefore useful in the treatment of
arthropathy, dermatological conditions, bone
resorption, inflammatory diseases and tumour invasion
and in the promotion of wound healing. Specifically,
compounds of the present invention may be useful in the
treatment of osteopenias such as osteoporosis,
rheumatoid arthritis, osteoarthritis, periodontitis,
gingivitis, corneal ulceration and tumour invasion.

A number of small peptide like compounds which
inhibit metalloproteases have been described. Perhaps
the most notable of these are those relating to the
angiotensin converting enzyme (ACE) where such agents act to block the conversion of the decapeptide angiotensin I to angiotensin II a potent pressor substance. Compounds of this type are described in EP-A-0012401.

Certain hydroxamic acids have been suggested as collagenase inhibitors as in US-A-4599361 and EP-A-0236872. Other hydroxamic acids have been prepared as ACE inhibitors, for example in US-A-4105789, while still others have been described as enkephalinase inhibitors as in US-A-4496540.

EP-A-0012401 discloses antihypertensive compounds of the formula:

\[
\begin{align*}
\text{O} & \text{R}_1^3 \text{R}_2^4 \text{R}_5^4 \text{R}_6^5 \text{O} \\
\text{R}^-\text{C}^-\text{C}^-\text{NH}^-\text{CH}^-\text{C}^-\text{N}^-\text{--C}^-\text{--C}^-\text{--R}^-^6 \\
\text{R}_2^6 & \text{O} \text{R}_7^7
\end{align*}
\]

wherein

R and R⁶ are the same or different and are hydroxy, alkoxy, alkenoxy, dialkylamino alkoxy, acylamino alkoxy, acyloxy alkoxy, aryloxy, alkyloxy, substituted aryloxy or substituted aralkoxy wherein the substituent is methyl, halo, or methoxy, amino, alkylamino, dialkylamino, aralkylamino or hydroxyamino;

R² is hydrogen, alkyl of from 1 to 20 carbon atoms, including branched, cyclic and unsaturated alkyl groups;
substituted alkyl wherein the substituent is halo, hydroxy, alkoxy, aryloxy amino, alkylamino, dialkylamino, acrylamino, arylamino, guanidino, imidazolyl, indolyl, mercapto, alkylthio, arylthio, carboxy, carboxamido, carbalkoxy, phenyl, substituted phenyl wherein the substituent is alkyl, alkoxy or halo; aralkyl or heteroaralkyl, aralkenyl or heteroaralkeny1, substituted aralkyl, substituted heteroaralkyl, substituted aralkenyl or substituted heteroaralkenyl, wherein the substituent is halo or dihalo, alkyl, hydroxy, alkoxy, amino, aminomethyl, acrylamino, dialkylamino, alkylamino, carboxyl, haloalkyl, cyano or sulphonamido, aralkyl or heteroaralkyl substituted on the alkyl portion by amino or acylamino;

\( R^2 \) and \( R^7 \) are hydrogen or alkyl;

\( R^3 \) is hydrogen, alkyl, phenylalkyl, aminomethylphenylalkyl, hydroxyphenylalkyl, hydroxyalkyl, acetylaminoalkyl, acylaminoalkyl, acylaminoalkyl aminoalkyl, dimethylaminoalkyl, haloalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl and alkylthioalkyl;

\( R^4 \) is hydrogen or alkyl;

\( R^5 \) is hydrogen, alkyl, phenyl, phenylalkyl, hydroxyphenylalkyl, hydroxyalkyl, aminooalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl or alkylthioalkyl;
R^4 and R^5 may be connected together to form an alkylene
bridge of from 2 to 4 carbon atoms, an alkylene bridge
of from 2 to 3 carbon atoms and one sulphur atom, an
alkylene bridge of from 3 to 4 carbon atoms containing
a double bond or an alkylene bridge as above,
substituted with hydroxy, alkoxy or alkyl and the
pharmaceutically acceptable salts thereof.

US-A-4599361 discloses compounds of the formula:

```
O  O  R^2  O
```

```
HOHNC-A-CNHz-CH-CNHR^1
```

wherein
R^1 is C_1^-C_6 alkyl;
R^2 is C_1^-C_6 alkyl, benzyl, benzyloxybenzyl, (C_1^-C_6
alkoxy)benzyl or benzyloxy(C_1^-C_6 alkyl);
a is a chiral centre with optional R or S
stereochemistry;
A is a

```
-(CHR^3^-CHR^4)- group
```

```
b     c
```

or a -(CR^3=CR^4)- group wherein b and c are chiral
centres with optional R or S stereochemistry;
R^3 is hydrogen, C_1^-C_6 alkyl, phenyl or phenyl(C_1^-C_6
alkyl) and R^4 is hydrogen, C_1^-C_6 alkyl, phenyl(C_1^-C_6
alkyl), cycloalkyl or cycloalkyl(C_1^-C_6 alkyl).

EP-A-0236872 discloses generically compounds of the
formula
A represents a group of the formula HN(OH)-CO- or HCO-N(OH)-

R\textsuperscript{1} represents a C\textsubscript{2}-C\textsubscript{5} alkyl group;

R\textsuperscript{2} represents the characterising group of a natural alpha-amino acid in which the functional group can be protected, amino groups may be acylated and carboxyl groups can be amidated, with the proviso that R\textsuperscript{2} can not represent hydrogen or a methyl group;

R\textsuperscript{3} represents hydrogen or an amino, hydroxy, mercapto, C\textsubscript{1}-C\textsubscript{6} alkyl, C\textsubscript{1}-C\textsubscript{6} alkoxy, C\textsubscript{1}-C\textsubscript{6} acylamino, C\textsubscript{1}-C\textsubscript{6} alkylthio, ary1-(C\textsubscript{1}-C\textsubscript{6} alkyl)-, amino-(C\textsubscript{1}-C\textsubscript{6}-alkyl)-, hydroxy(C\textsubscript{1}-C\textsubscript{6}-alkyl)-, mercapto(C\textsubscript{1}-C\textsubscript{6} alkyl) or carboxy(C\textsubscript{1}-C\textsubscript{6} alkyl) group, wherein the amino, hydroxy, mercapto or carboxyl groups can be protected and the amino groups may be acylated or the carboxyl groups may be amidated;

R\textsuperscript{4} represents hydrogen or a methyl group;
6

R⁵ represents hydrogen or a C₁-C₆ acyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, di(C₁-C₆-alkoxy)methylene, carboxy, (C₁-C₆ alkyl)carbinyl, (C₁-C₆ alkoxy)carbinyl, arylmethoxy carbinyl, (C₁-C₆ alkyl)amino carbinyl or arylamino carbinyl group; and

R⁶ represents hydroxy or a methylene group; or

R² and R⁴ together represent a group-(CH₂)ₙ-, wherein n represents a number from 4 to 11; or

R⁴ and R⁵ together represent a trimethylene group;

and pharmaceutically acceptable salts of such compounds, which are acid or basic.

US-A-4105789 generically discloses compounds which have the general formula

\[ R₃ \quad R₁ \]
\[ R₄-OC-(CH₂)ₙ-CH-CO-N-CH-COOH \]

and salts thereof, wherein

R₁ is hydrogen, lower alkyl, phenyl lower alkylene, hydroxy-lower alkylene, hydroxyphenyl lower alkylene, amino-lower alkylene, guanidine lower alkylene, mercapto-lower alkylene, lower alkyl-mercapto-lower alkylene, imidazolyl lower alkylene, indolyl-lower alkylene or carbamoyl lower alkylene;

R₂ is hydrogen or lower alkyl;

R₃ is lower alkyl or phenyl lower alkylene;
R₄ is hydroxy, lower alkoxy or hydroxyamino; and
n is 1 or 2.

US-A-4496540 discloses compounds of the general
formula:

A-B-NHOH

wherein A is one of the aromatic group-containing amino
acid residues L-tryptophyl, D-tryptophyl, L-tyrosyl,
D-tyrosyl, L-phenylalanyl, or D-phenylalanyl, and B is
one of the amino acids glycine, L-alanine, D-alanine,
L-leucine, D-leucine, L-isoleucine, or D-isoleucine;
and pharmaceutically acceptable salts thereof.

It would be desirable to improve on the solubility of
known collagenase inhibitors and/or stromelysin
inhibitors (whether as the free base or the salt) and,
furthermore, increases in activity have also been
sought. It is not a simple matter, however, to predict
what variations in known compounds would be desirable
to increase or even retain activity; certain
modifications of known hydroxamic acid derivatives have
been found to lead to loss of activity.

According to a first aspect of the invention, there is
provided a compound of general formula I:

\[
\begin{array}{c}
\text{HO} \\
\text{N} \\
\text{R}^1 \\
\text{R}^2 \\
\text{R}^3 \\
\text{R}^4 \\
\text{R}^5
\end{array}
\]

(\text{I})
wherein:

$R^1$ represents a hydrogen atom or a $C_1-C_6$ alkyl, $C_1-C_6$ alkenyl, phenyl, phenyl($C_1-C_6$)alkyl, $C_1-C_6$ alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl($C_1-C_6$)alkylthiomethyl or heterocyclylthiomethyl group; or $R^1$ represents $-S-R^X$ wherein $R^X$ represents a group

$R^2$ represents a hydrogen atom or a $C_1-C_6$ alkyl, $C_1-C_6$ alkenyl, phenyl($C_1-C_6$)alkyl, cycloalkyl($C_1-C_6$)-alkyl, or cycloalkenyl($C_1-C_6$)alkyl;

$R^3$ represents an amino acid side chain or a $C_1-C_6$ alkyl, benzyl, ($C_1-C_6$)alkoxybenzyl, benzyloxy-($C_1-C_6$)alkyl or benzyloxybenzyl group;

$R^4$ represents a hydrogen atom or a methyl group;

$R^5$ represents a group $(CH_2)_nA$;

or $R^4$ and $R^5$ together represent a group
Q represents CH₂ or CO;

m is an integer from 1 to 3;

n is an integer from 1 to 6; and

A represents a hydroxy, (C₁-C₆)alkoxy, (C₂-C₇)acyloxy, (C₁-C₆)alkylthio, phenylthio, (C₂-C₇)acylamino or N-pyrrolidone group

or a salt and/or N-oxide and/or (where the compound is a thio-compound) a sulphoxide or sulphone thereof.

Hereafter in this specification, the term "compound" includes "salt" unless the context requires otherwise.

As used herein the term "C₁-C₆ alkyl" refers to a straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl and hexyl, and cognate terms (such as "C₁-C₆ alkoxy") are to be construed accordingly.

The term "C₁-C₆ alkenyl" refers to a straight or branched chain alkyl moiety having one to six carbons and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include, for example, an alpha, beta-unsaturated methylene, vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl.
The term "cycloalkyl" refers to a saturated alicyclic moiety having from 3 to 8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "cycloalkenyl" refers to an unsaturated alicyclic moiety having from 3 to 8 carbon atoms and includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl.

The term "heterocyclylthiomethyl" refers to a methyl group substituted by a heterocyclic thiol for example pyridine-2-thiol, pyridine-4-thiol, thiophene-2-thiol or pyrimidine-2-thiol.

The term "substituted", as applied to a phenyl or other aromatic ring, means substituted with up to four substituents each of which independently may be C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy, thiol, C₁-C₆ alkylthiol, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -COONH₂ or -CONH₂R, wherein R represents a C₁-C₆ alkyl group or the characteristic side chain of an amino acid such as alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine or histidine.

The term "amino acid side chain" means a characteristic side chain attached to the -CH(NH₂)(COOH) moiety in the following R or S amino acids: glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine,
tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid and aspartic acid.

There are several chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereomers with the appropriate R or S stereochemistry at each chiral centre. General formula I and, where appropriate, all other formulae in this specification are to be understood to include all such stereoisomers and mixtures (for example racemic mixtures) thereof. Compounds in which the chiral centre adjacent the substituent R^3 has S stereochemistry are preferred.

Further or other preferred compounds include those in which, independently or in any combination:

R^1 represents a hydrogen atom or a C_1-C_4 alkyl (such as methyl), phenylthiomethyl or heterocyclylthiomethyl (such as thiophenylthiomethyl) group;
R^2 represents a C_3-C_6 alkyl (such as isobutyl or n-pentyl) group;
R^3 represents a benzyl, 4-(C_1-C_6)alkoxyphenylmethyl or benzyloxy benzyl group;
R^4 represents a hydrogen atom or
R^4 and R^5 together represent a group

CH_2OH
n has the value 1, 2 or 3; and/or
A represents a hydroxy, methoxy, acetoxy,
acetylamino, thioethyl or N-pyrrolidone group.

Particularly preferred compounds include:

1. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalanine-N-(2-hydroxyethyl)-amide;
2. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalaninyl-proline;
3. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalanine-N-(2-hydroxyethyl)-N-methylamide;
4. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalaninyl-D-prolinol;
5. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalaninyl-L-prolinol;
6. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalanine-N-(5-N-methyl-pentylcarboxamide)
   amide;
7. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalanine-N-(2-ethyl thioethyl) amide;
8. \[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-
   phenylalanine-N-(2-methoxyethyl) amide;
9. \(\text{[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-N-acetylethyl) amide;}\)

10. \(\text{[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide;}\)

11. \(\text{[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide sodium salt;}\)

12. \(\text{[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-acetoxyethyl) amide;}\)

13. \(\text{[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide;}\)

14. \(\text{[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-methyl-N-(2-hydroxyethyl) amide;}\)

15. \(\text{[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(2-hydroxyethyl) amide;}\)

16. \(\text{[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalaninyl-D-prolinol;}\)

17. \(\text{[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide sodium salt;}\)
and free bases, free acids and salts thereof, where appropriate. Compounds 13 and 10 are especially preferred and compound 13 is the most preferred.

Compounds of general formula I may be prepared by any suitable method known in the art and/or by the following process, which itself forms part of the invention.

According to a second aspect of the invention, there is provided a process for preparing a compound of general formula I as defined above, the process comprising:

(a) deprotecting (for example by hydrogenating) a compound of general formula III

\[
\text{(III)}
\]

wherein:

\[R^1, R^2, R^3, R^4 \text{ and } R^5 \text{ are as defined in general formula I and } Z \text{ represents a protective group, such as a benzyl group; or}
\]

(b) reacting a compound of general formula IV

\[
\text{(IV)}
\]

wherein:
R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined in general formula I,

with hydroxylamine or a salt thereof; and

(c) optionally after step (a) or step (b) converting a compound of general formula I into another compound of general formula I.

Compounds of general formula I which are sulphoxides or sulphones can be derived from thiol compounds of general formula I by oxidation. Alternatively, thiols of general formula III or IV can be oxidised. Compounds of general formula I which are disulphides (ie compounds wherein R<sup>1</sup> represents SR<sup>x</sup>) may be derived from thiol compounds of general formula I by mild oxidation with, for example, iodine in methanol.

A compound of general formula III can be obtained by coupling, for example by conventional coupling techniques, a compound of general formula IV with an O-protected (for example benzyl) hydroxylamine or by reacting a compound of general formula V

\[
\begin{align*}
\text{ZONH} & \quad \text{OH} \\
\text{R<sup>1</sup> O R<sup>3</sup> (V)}
\end{align*}
\]

wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in general formula I and Z represents a protective group such as benzyl,
with a compound of general formula VI

\[ \text{NHR}^4\text{R}^5 \]  
(VI)

A compound of general formula V may be prepared by hydrolysis in the presence of a base such as sodium hydroxide of a compound of general formula VII

\[
\begin{array}{c}
\text{Z} \text{N} \text{O} \\
\text{H} \text{R}^1 \text{O} \\
\text{R}^2 \text{H} \text{N} \text{O} \\
\text{R}^3 \text{R}^6
\end{array}
\]  
(VII)

wherein:

- \( R^1, R^2 \) and \( R^3 \) are as defined in general formula I,
- \( R^6 \) represents a \( C_1-C_6 \) alkoxy, benzyloxy or substituted (e.g., 4-nitro) benzyloxy group, and \( Z \) represents a protective group.

A compound of general formula VII may be prepared by coupling, for example by conventional coupling techniques, a compound of general formula VIII with an O-protected (for example benzyl) hydroxylamine

\[
\begin{array}{c}
\text{O} \text{R}^2 \text{H} \text{N} \text{O} \\
\text{R}^1 \text{O} \\
\text{R}^3 \text{R}^6
\end{array}
\]  
(VIII)

wherein:
R¹, R² and R³ are as defined in general formula I and R⁶ represents a C¹-C⁶ alkoxy, benzyloxy or substituted benzyloxy group.

A compound of general formula VIII may be prepared by hydrogenating and (eg thermally) decarboxylating a compound of general formula IX

\[
\begin{align*}
\text{(IX)}
\end{align*}
\]

wherein:

R¹, R² and R³ are as defined in general formula I, R⁸ represents a C¹-C⁶ alkyl or benzyl group, R⁶ represents a C¹-C⁶ alkoxy, benzyloxy or substituted benzyloxy group and R⁷ represents a C¹-C⁶ alkoxy carbonyl or benzyloxy carbonyl group.

A compound of general formula IX may be prepared by reacting a substituted acid of general formula X

\[
\begin{align*}
\text{(X)}
\end{align*}
\]

wherein:
R\(^1\) and R\(^2\) are as defined in general formula I, R\(^8\) represents a C\(_1\)–C\(_6\) alkyl or benzyl group and R\(^7\) represents a C\(_1\)–C\(_6\) alkoxy or benzyloxy group, with R\(^3\) represents a C\(_1\)–C\(_6\) alkyl or benzyl group and R\(^7\) represents a C\(_1\)–C\(_6\) alkoxy or benzyloxy group, with the amino acid derivative of general formula (XI)

\[
\text{NH}_2 \quad \text{O} \\
\text{R}^3 \quad \text{R}^6
\]

wherein:

R\(^3\) is as defined in general formula I and R\(^6\) represents a C\(_1\)–C\(_6\) alkoxy, benzyloxy or substituted benzyloxy group.

Alternatively, a compound of general formula IV can be prepared by de-esterifying (for example hydrolysing, under acid or base catalysis) a compound of general formula XII

\[
\text{O} \quad \text{R}^2 \quad \text{H} \quad \text{H} \quad \text{O} \\
\text{R}^1 \quad \text{R}^3 \quad \text{R}^4 \quad \text{R}^5
\]

wherein:

R\(^1\), R\(^2\), R\(^3\), R\(^4\) and R\(^5\) are as defined in general formula I and R\(^8\) represents a C\(_1\)–C\(_6\) alkyl or benzyl group.
A compound of general formula XII can be prepared in a manner analogous to the preparation of a compound of formula IX by reacting a substituted acid of general formula XIII.
wherein:

R₁ and R² are as defined in general formula I and R₈ represents a C₁-C₆ alkyl or benzyl group,

with an amino acid derivative of general formula XIV

wherein:

R₃, R⁴ and R⁵ are as defined in general formula I.

In a further synthetic variant, a compound of general formula X as defined above wherein R¹ represents a hydrogen atom can be reacted with a compound of general formula XIV to produce a compound of general formula XV
wherein:

R², R³, R⁴ and R⁵ are as defined in general formula I, R⁸ represents a C₁-C₆ alkyl or benzyl group and R⁷ represents a C₁-C₆ alkoxy carbonyl or benzyloxy carbonyl group.

A compound of general formula XV wherein R⁸ represents benzyl and R¹ represents benzyloxy carbonyl may be hydrogenated to the malonic acid, then treatment with aqueous formaldehyde and piperidine gives a compound of formula XVI

![chemical structure](image)

wherein:

R², R³, R⁴ and R⁵ are as defined in general formula I.

Compounds of general formula XVI, by treatment with the appropriate thiols give the acids of general formula IV where R¹ is a substituted thiomethyl derivative. Thiomethyl derivatives can be oxidised to sulphoxides and sulphones as appropriate.

The starting materials (compounds of general formulae IX, X, XIII and XIV) and reagents described above are either commercially available or may be produced by conventional processes from commercially
available materials. For example, when $R^1$ represents a hydrogen atom, the substituted acid of general formula XIII may be prepared by reaction of an aldehyde XVII

$$R^9\text{CHO}$$

(XVII)

wherein $R^9$ represents a hydrogen atom or a $C_1$-$C_5$ alkyl, $C_1$-$C_5$ alkenyl, phenyl ($C_1$-$C_5$) alkyl, cycloalkyl ($C_1$-$C_5$) alkyl or cycloalkenyl ($C_1$-$C_5$) alkyl group, with a succinate derivative of general formula XVIII,

$$R^8\text{O}_2\text{C} \equiv \text{CO}_2\text{R}^8$$

(XVIII)

wherein:

$R^8$ represents a $C_1$-$C_6$ alkyl or benzyl group

under base catalysis to give a mixture of acids of general formulae XIXa and XIXb

$$\text{CO}_2\text{R}^8$$

(XIXa)

$$\text{CO}_2\text{H}$$

(XIXb)

which by hydrogenation, esterification and hydrolysis can be converted to the acids of the general formula XIII.

Alternatively an ester of general formula XX may be reacted with an ester stabilised phosphorane of general formula XXI.
to yield a compound of general formula XXII

\[
\begin{align*}
R_2 & \quad \text{CO}_2R^8 \\
\text{XXII}
\end{align*}
\]

wherein \(R^8\) represents a \(C_1\text{-}C_6\) alkyl group, which can be further converted by hydrogenation to the acids of general formula XIII.

In addition the substituted esters may be prepared by reacting an ester of the general formula XXIII

\[
\begin{align*}
\text{XXIII}
\end{align*}
\]

wherein \(Y\) represents halo and \(R^8\) is as defined above and \(R^{10}\) is either \(R^1\) or \(R^2\) as defined above, with a malonate derivative of the general formula XXIV

\[
\begin{align*}
\text{XXIV}
\end{align*}
\]

wherein \(R^{11}\) is \(R^2\) or \(R^1\) as defined above, and the alternative to that substituent employed in the halo ester.
Compounds of general formulae III and IV are valuable intermediates in the preparation of compounds of general formula I. According to a third aspect of the invention, there is therefore provided a compound of general formula III. According to a fourth aspect of the invention, there is provided a compound of general formula IV.

As mentioned above, compounds of general formula I are useful in human or veterinary medicine as they are active inhibitors, of metalloproteases involved in tissue degradation.

According to a fifth aspect of the invention, there is provided a compound of general formula I for use in human or veterinary medicine, particularly in the management (by which is meant treatment of prophylaxis) of disease involving tissue degradation, in particular rheumatoid arthritis, and/or in the promotion of wound healing.

According to a sixth aspect of the invention, there is provided the use of a compound of general formula I in the preparation of an agent for the management of disease involving tissue degradation, particularly rheumatoid arthritis, and/or in the promotion of wound healing. Compounds of general formula I can therefore be used in a method of treating disease involving tissue degradation, particularly rheumatoid arthritis, and/or in a method of promoting wound healing, the method in either case comprising administering to a human or animal patient an effective amount of a compound of general formula I.
The potency of compounds of general formula I to act as inhibitors of collagenase (a metalloprotease involved in tissue degradation) was determined by the procedure of Cawston and Barrett, (Anal. Biochem., 99, 340-345, 1979) and their potency to act as inhibitors of stromelysin was determined using the procedure of Cawston et al (Biochem. J., 195, 159-165 1981), both of which techniques are to be described more fully in the examples and, to the extent that the law allows, are incorporated by reference herein.

According to a seventh aspect of the invention, there is provided a pharmaceutical or veterinary formulation comprising a compound of general formula I and a pharmaceutically and/or veterinarily acceptable carrier. One or more compounds of general formula I may be present in association with one or more non-toxic pharmaceutically and/or veterinarily acceptable carriers and/or diluents and/or adjuvants and if desired other active ingredients.

According to an eighth aspect of the invention, there is provided a process for the preparation of a pharmaceutical or veterinary formulation in accordance with the seventh aspect, the process comprising admixing a compound of general formula I and a pharmaceutically and/or veterinarily acceptable carrier.

Compounds of general formula I may be formulated for administration by any route and would depend on the disease being treated. The may be in the form of
tablets, capsules, powders, granules, lozenges, liquid
or gel preparations, such as oral, nasal, topical,
or sterile parenteral solutions or suspensions.

Tablets and capsules for oral administration may be in
unit dose presentation form, and may contain
conventional excipients such as binding agents, for
example syrup, acacia, gelatin, sorbitol, tragacanth,
or polyvinyl-pyrrolidone; fillers for example
lactose, sugar, maize-starch, calcium phosphate,
sorbitol or glycine; tableting lubricant, for example
magnesium stearate, talc, polyethylene glycol or
silica; disintegrants, for example potato starch, or
acceptable wetting agents such as sodium lauryl
sulphate. The tablets may be coated according to
methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for
example, aqueous or oily suspensions, solutions,
emulsions, syrups or elixirs, or may be presented as a
dry product for reconstitution with water or other
suitable vehicle before use. Such liquid
preparations may contain conventional additives such
as suspending agents, for example sorbitol, syrup,
methyl cellulose, glucose syrup, gelatin,
hydrogenated edible fats; emulsifying agents, for
example lecithin, sorbitan monooleate, or acacia;
non-aqueous vehicles (which may include edible
oils), for example almond oil, fractionated coconut
oil, oily esters such as glycerine, propylene glycol,
or ethyl alcohol; preservatives, for example methyl or
propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

The dosage unit involved in oral administration may contain from about 1 to 250 mg, preferably from about 25 to 250 mg, of a compound of general formula I. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and will ultimately depend on the judgement of the physician or veterinarian. However, a dose of a compound of general formula I of about 0.1 to 300 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight may be appropriate.

For topical application to the skin the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations that may be used for the drug are conventional formulations well known in the art, for example, as described in standard text books of pharmaceutics such as the British Pharmacopoeia.

For topical applications to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non-aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents, such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorohexidine, and thickening agents such as hypropemellose may also be included.
The dosage employed for the topical administration will, of course, depend on the size of the area being treated. For the eyes each dose will be typically in the range from 10 to 100 mg of the compound of general formula I.

The active ingredient may also be administered parenterally in a sterile medium. The drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.

For use in the treatment of rheumatoid arthritis the compounds of this invention can be administered by the oral route or by injection intra-articularly into the affected joint. The daily dosage for a 70 kg mammal will be in the range of 10 mg to 1 gram of a compound of general formula I.

The following examples illustrate the invention, but are not intended to limit the scope in any way.

The following abbreviations have been used in the Examples:-

DCC - Dicyclohexylcarbodiimide
DCM - Dichloromethane
DCU - Dicyclohexylurea
DIPE - Diisopropyl ether
DMF - N,N-dimethylformamide
HOBT - Hydroxybenztriazole
Example 1

\[ \text{[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-hydroxyethy1)-amide} \]

\[
\begin{array}{c}
\text{CONH} \\
\text{Ph} \\
\text{H} \\
\text{H} \\
\text{N} \\
\text{O} \\
\text{CONH} \\
\text{OH}
\end{array}
\]

(a) \[ \text{[4-Benzylbxyoxy-3-benzylxycarbony1-2R-isobutylsuccinyl]-L-phenylalanine methyl ester} \]

Benzyl (2-benzyloxyxycarbony1-5-methyl-3R-tart-butoxy carbony1)-hexanoate (52g, 115 mmol) was stirred at room temperature with 5% water in TFA (250 ml) for 1.5h. After this time the TFA was evaporated under reduced pressure then the residue was azeotroped with toluene (3 x 250 ml).

The crude acid from this reaction was dissolved in DCM/DMF (4:1), then HOBT (16g, 118 mmol), NMM (12g, 118 mmol) and WSCDI (22g, 115 mmol) were added at room temperature. After 20 minutes a further equivalent of NMM (12g, 118 mmol) was added followed by
L-phenylalanine methyl ester hydrochloride (23g, 107 mmol). This solution was stirred overnight and then concentrated under vacuum. The oily residue was dissolved in DCM then washed with 10% citric acid (2x250 ml), with 10% sodium bicarbonate (2x250 ml) and once with saturated brine (250 ml). The organic layer was dried (sodium sulphate), filtered then the solvent removed under reduced pressure to give the title compound as an oil (50.9g, 79%).

δ_H (250MHz, CDCl_3, 3:1 mixture of diastereomers)

Major diastereomer 0.72 (3H, d, J= 6 Hz, CH(CH_3)_2), 0.74 (3H, d, J= 6 Hz, CH(CH_3)_2), 0.80 - 1.00 (2H, m, CHCH_2 + CHMe_2), 1.40 - 1.60 (2H, m, CHCH_2 + CHCH_2), 2.95 (1H, dd, J= 14.6 Hz, CH_2Ph), 3.07 (1H, dd, J= 14.5 Hz, CH_2Ph), 3.64 (3H, s, CO_2Me), 3.82 (1H, d, J= 10 Hz, CH(CO_2Bn)_2), 4.82 (1H, m, CHCO), 5.0 - 5.2 (2H, m, OCH_2Ph), 6.2 (1H, d, J= 8 Hz, NH), and 7.10 - 7.40 (15H, m, Ph). Minor diastereomer shows 0.63 (3H, d, J= 6 Hz, CH(CH_3)_2), 0.68 (3H, d, J= 6 Hz, CH(CH_3)_2), 3.67 (3H, s, CO_2Me), and 3.75 (1H, d, J= 8 Hz, CH(CO_2Bn)_2)

(b) [4-Hydroxy-2R-isobutylsuccinyl]-L-phenylalanine methyl ester

The product from above (50.9g, 91 mmol) was dissolved in ethanol (100ml) and stirred at room temperature with activated charcoal pellets for 1h. 10% Palladium on charcoal (20g) in ethyl acetate was slurried into the ethanoic solution. Cyclohexene (20ml) in ethanol (100ml) was added and the mixture was brought to reflux for 5h. The reaction mixture was filtered to remove
the catalyst, then the solvents evaporated under reduced pressure to leave a yellow oil (29.8g). This oil was taken up in xylene (500ml) and heated at reflux for 10 minutes. The xylene was removed under reduced pressure to leave the crude material as an oil (26.5g).

(c)\{4-(N-Benzoyloxyamino)-2R-isobutylsuccinyl\}-L-phenylalanine methyl ester

The crude acid (26.5g, 79mmol) was dissolved in DCM/DMF (4:1, 500ml), then NMM (9.6g, 95mmol), HOBT (12.8g 95mmol) and WSCDI (18.2g, 95mmol) added and the mixture stirred at room temperature until tlc indicated complete conversion to the activated ester (about 10 minutes). To this solution containing the active ester was added benzylhydroxylamine hydrochloride (15.2g, 95mmol) and a further equivalent of NMM (9.6g, 95mmol) in the solvent mixture (80ml). After stirring at room temperature overnight DCM (250ml) was added then the mixture washed with citric acid (2x250ml), 10% sodium bicarbonate solution (2x250ml) and brine (250ml) then finally dried over sodium sulphate. The solution was filtered and the solvent removed under reduced pressure to give an oil (27.2g) which was purified by column chromatography using ether as an eluant to give the title compound (11g, 23.7mmol, 30%).

\(\delta_{H} (250\text{MHz, CDCl}_3) 0.84 (6H, \text{m, CH(CH}_3)_2), 1.16 (1H, \text{m, CHMe}_2), 1.51 (2H, \text{m, CH}_2\text{CHMe}_2), 2.1 - 2.4 (2H, \text{bm, CH}_2\text{CONHOBn}), 2.73 (1H, \text{m, CH}_2\text{CHCO}), 3.06 (2H, \text{d, J= 6})\)
4

[4-(N-Benzylamino)-2R-isobutylsuccinyl]-L-phenylalanine methyl ester (9.5g, 21mmol) was dissolved in methanol (200ml) and lithium hydroxide solution (0.5N, 84ml, 42mmol) was added with stirring at room temperature. When the reaction was complete, as judged from tlc, the methanol was removed by evaporation and the remaining aqueous phase was acidified to pH1 with citric acid. The precipitated solid was filtered off and dried, while the filtrate was extracted with DCM (500ml) and dried over sodium sulphate. Solvent removal from the organic phase left an oil (5.38g) which could be recrystallised from diisopropyl ether and methanol to give material which was identical with the solid which precipitated during acidification. These two batches were combined to give the title compound (6.40g, 15mmol, 71%)

m.p. 161-162°C

\nu_{\text{max}}(KBr) \quad 3300, 3020, 2980, 1710, 1650, 1630, 1550, 1265, 740, \text{and} \quad 700 \text{ cm}^{-1}

\delta_H (250MHz, CDCl_3/D_6-DMSO) 0.80 - 0.87 (7H, m), 1.50 (2H, bm), 2.0 - 2.1 (2H, m), 2.91 - 3.14 (2H, m, CH_2) Ph), 4.77 (2H, s, OCH_2) Ph), and 7.18 - 7.36 (10H, m, Ph).
\[ \delta (62.9 \text{MHz}, \text{D}_6-\text{DMSO}) 174.1, 173.1, 167.7, 137.9, 129.2-126.4, 76.9, 53.3, 40.7, 39.9, 36.8, 35.8, 25.3, 23.5, \text{and} 22.1 \]

6. \([4-(\text{N-Hydroxyamino})-2\text{R-isobutylsuccinyl}]\text{-L-phenylalanine-N-(2-hydroxyethyl)-amide}\]

7. \([4-(\text{N-Benzylamino})-2\text{R-isobutylsuccinyl}]\text{-L-phenylalanine}\) (7.50g, 17.6mmol) was dissolved in DCM (100ml) and cooled in ice. Triethylamine (1.96g, 19.4mmol) was added together with ethylchloroformate (2.10g, 19.4mmol) and after 10 minutes ethanolamine (1.55g, 21.1mmol) in DCM (10ml) was added. After 3h at room temperature the reaction mixture was diluted with ethyl acetate then washed with sodium bicarbonate solution and brine, and finally dried over sodium sulphate.

Solvent removal under reduced pressure gave the crude benzyl hydroxamate which was recrystallised from ethyl acetate/hexane (2.6g, 5.5mmol)

The crude material from above was dissolved in cyclohexene/ethanol (10% solution, 55ml), 10% palladium on charcoal (250mg) was added then the mixture refluxed until starting material had dissappeared by tlc (ca. 30 minutes). The catalyst was removed by filtration, and the solvent removed under reduced pressure to leave a solid which could be recrystallised from methanol and DIPE. The required product (1.54g, 4.00mmol, 74%) was collected by filtration.

m.p. 156-158°C
\([\alpha]_D = -21.5 \ (c=1, \text{MeOH})\)

\(\nu_{\text{max}}(\text{KBr})\): 3300, 2950, 1650, 1550, and 700 cm\(^{-1}\)

\(\delta_{\text{H}}\) (250 MHz, CDCl\(_3\)): 0.72 (3H, d, J = 6 Hz, CH(\text{CH}_3)_2),
0.77 (3H, d, J = 6 Hz, CH(\text{CH}_3)_2),
0.95 (1H, m, CHCH)_2,
1.28 (2H, m, \text{CH(}CH(\text{CH}_3)_2 + \text{CHCH}_2),
1.92 (2H, m,
2.61 (1H, bm, CHCHO),
2.80 (1H, dd, J =
3.79 Hz, CH(\text{CH}_3)_2),
3.00 - 3.20 (3H, m, NCH\(_2\) + CH\(_2\)Ph),
4.41 (1H, m, NCHCO),
4.65 (1H, bt, OH),
7.22 (5H, m, Ph),
7.86 (1H, t, J = 6 Hz, CONHC\(_2\)_2),
8.07 (1H, d, J = 8 Hz, CONH), and
8.76 (1H, s, NHOH).

\(\delta_{\text{C}}\) (62.9 MHz, D\(_6\)DMSO): 174.0, 171.2, 138.3, 129.2,
128.1, 126.2, 59.8, 54.0, 41.6, 37.3, 35.8, 25.3, 23.5,
and 20.0.

Analysis calculated for C\(_{19}\)H\(_{29}\)N\(_3\)O\(_5\):
Requires C 60.14 H 7.70 N 11.07
Found C 59.97 H 7.68 N 11.10

**Example 2**

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenyl-
analanyl-proline

[Chemical structure diagram]
Using the procedure described in Example 1e [4-(N-Benzylamino)-2R-isobutylsuccinyl]-L-phenylalanine (1.8g, 4.2mmol) was coupled with L-proline benzylester hydrochloride (1.21g, 5.00mmol) then the product hydrogenated to give the title compound (34mg, 78.5 mumol, 2%)

\[
\delta_H (250MHz, D_6 -DMSO) 0.78 (6H, 2xd, J= 6Hz, CH(CH_3)_2), 0.96 (1H, m, CH_2CHMe_2), 1.36 (2H, m, CH_2CHMe_2), 1.86 (6H, m, CH_2CONHOH and NCH_2CH_2), 2.79 (1H, dd, J= 15.9 Hz, CH_2Ph), 2.97 (1H, dd, J= 14, 6 Hz, CH_2Ph), 3.43 and 3.64 (2H, m, CH_2N), 4.23 (1H, m, NCHCO_2H), 4.66 (1H, NHCHCONH), 7.30 (5H, m, Ph), 8.24 (1H, d, J= 8Hz, NH), and 8.69 (1H, s, OH)
\]

\[
\delta_C (62.9MHz, D_6 -DMSO) 174.2, 173.4, 169.4, 167.2, 137.8, 129.4, 128.2, 126.4, 59.8, 51.8, 48.5, 40.5, 39.8, 36.6, 35.8, 28.8, 25.4, 24.7, 23.5, and 22.0
\]

Example 3


Using the procedure described in Example 1e [4-(N-Benzylamino)-2R-isobutylsuccinyl]-L-phenylalanine (0.5g, 1.17mmol) was coupled with
N-methylethanolamine (100mg, 1.29mmol) then the product hydrogenated to give the title compound (97mg, 0.25 mmol, 21%) m.p. 136.0 - 137.0°C [α]D +1.1 (c=1, MeOH) 

νmax(KBr) 3600 - 3100, 2960, 1680, 1560, 940, 750, and 700 cm⁻¹

δH (250MHz, CDCl₃/D₆-DMSO, 1:1) 0.74 (6H, m, CH(CH₃)₂), 1.00 (1H, m, CH₂CHMe₂), 1.36 (2H, m, CH₂CHMe₂), 2.00 (2H, m, CH₂NHOH), 2.60 - 3.00 (3H, m + 3H, 2xs), 3.39 (2H, 4.42 - 4.70 (1H, m, OH), 4.80 - 5.00 (1H, m, CH₂Ph), 7.14 (5H, m, Ph), 7.97 (1H, d, J= 7Hz, NH), and 8.50 (1H, s, NHOH)

δC (62.9MHz, D₆-DMSO, 1:1 Mixture of Rotamers) 173.9, 173.8, 171.3, 170.3, 167.5, 138.2, 137.9, 129.4, 128.1, 126.4, 126.3, 58.7, 58.4, 51.2, 50.2, 50.0, 49.7, 40.7, 40.5, 39.8, 37.7, 37.4, 36.0, 35.9, 33.9, 25.4, 23.5, 23.4, and 22.1.

Example 4
[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalaninyl-D-prolinol.

Using the procedure described in Example 1e [4-(N-Benzylamino)-2R-isobutylsuccinyl]-L-phenylalanine (0.5g, 1.17mmol) was coupled with R-pyrrolidine methanol (130mg, 1.29mmol) then the product hydrogenated to give the title compound (150mg, 0.36 mmol, 31%)

m.p. 150.0 -155.0°C

[α]D = +21.4 (c=1, MeOH)

νmax(KBr) 3300, 2960, 1650, 1620, 1450, 1050, and 700 cm⁻¹

δH (250MHz, D6-DMSO) 0.80 (6H, m, CH(CH3)2), 1.10 - 2.1 (14H, m), 2.6 - 3.2 (6H, m), 4.6 (2H, m), 7.2 (5H, m, Ph), 8.3 (1H, d, J= 8Hz, NH), and 8.7 (1H, s, NHOH).

δC (62.9MHz, D6-DMSO), Major Rotamer shows 179.4, 175.0, 172.6, 142.8, 129.4, 128.1, 126.4, 60.7, 58.7, 52.1, 46.4, 41.1, 37.1, 35.8, 26.5, 25.5, 23.5, 23.2, 22.1, and 21.4; minor rotamer shows 179.4, 175.6, 172.6, 143.4, 127.4, 128.1, 126.2, 62.7, 61.3, 45.4, 40.5, 37.2, 35.8, 27.6, 25.6, 23.4, 22.1, and 21.4.
Example 5

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalaninyl-L-prolinol.

Using the procedure described in Example 1e [4-(N-Benzylamino)-2R-isobutylsuccinyl]-L-phenylalanine (0.5g, 1.17mmol) was coupled with S-pyrrrolidine methanol (130mg, 1.29mmol) then the product hydrogenated to give the title compound (106mg, 0.25 mmol, 22%)
m.p. 154.0 -155.0°C

[α]D = -0.3 (c=1, MeOH)

νmax(KBr) 3300, 2960, 1650, 1620, 1550, 1450, 1050, and 700 cm⁻¹

δH (250MHz, CDCl3/D6-DMSO, 1:1) 0.80 (6H, m, CH(CH₃)₂), 1.4 - 1.8 (14H, m), 2.7 - 3.6 (4H, m), 4.6 - 4.9 (3H, m), and 7.2 (5H, m, Ph).

δC (62.9MHz, D6-DMSO), Mayor rotamer shows 174.0, 169.8, 167.6, 137.6, 129.4, 129.2, 128.5, 61.8, 58.7, 52.2, 48.6, 40.8, 39.8, 37.5, 35.8, 28.5, 25.4, 23.5, 23.4, and 22.2; Minor rotamer 174.1, 169.7, 167.6,
Analysis calculated for C$_{22}$H$_{33}$N$_{3}$O$_{5}$
Required C 62.99 H 7.93 N 10.02
Found C 62.74 H 7.85 N 9.79

Example 6

(4-(N-Hydroxyamino)-2R-isobutylsuccinyl)-L-phenylalanine-N-(5-N-methyl-pentylcarboxamide) amide.

Using the procedure described in Example 1e
(4-(N-Benzylexyamino)-2R-isobutylsuccinyl)-L-phenylalanine (0.4g, 1.00 mmol) was coupled with N-methyl-(5-aminopentylcarboxamide) trifluoroacetic acid salt (1.00mmol) then the product hydrogenated to give the title compound (137mg, 0.25 mmol, 30%)
m.p. 149 - 151°C
[α]$_D$ = -13.7° (c=1.3, MeOH)
ν$_{max}$(KBr) 3290, 2950, 1655, 1640, and 1545 cm$^{-1}$
δ_H (250MHz, D_6-DMSO) 0.72 (3H, d, J = 6Hz, CH(CH_3)_2),
0.77 (3H, d, J = 6Hz, CH(CH_3)_2) 1.02 (1H, m), 1.31 (6H, m), 2.02 (4H, m), 2.54 (3H, d, J = 5Hz), 2.61 (1H, m),
2.84 (1H, dd, J = 9,14Hz), 3.01 (3H, m), 4.39 (1H, m),
7.21 (5H, m), 7.72 (1H, m), 7.82 (1H, t, J = 2Hz), 8.09
(1H, d, J = 8Hz), and 8.76 (1H, bs)

δ_C (62.9MHz, D_6-DMSO) 173.9, 172.5, 170.9, 167.6,
138.3, 129.2, 128.1, 126.2, 54.1, 40.8, 38.7, 38.4,
37.5, 35.8, 35.1, 28.7, 25.5, 25.3, 23.5, 22.7, and
22.0.

Example 7

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenyl-
alanine-N-(2-ethyl thioethyl) amide.

Using the procedure described in Example 1e
4-(N-Benzyloxyamino)-2R-isobutylsuccinyl]-L-phenyl-
alanine (0.5g, 1.17mmol) was coupled with
2-(thioethyl)-1-aminoethane hydrochloride (183mg,
1.29mmol) then the product hydrogenated to give the
title compound (163 mg).

m.p. 169 - 171°C

[a]_D = -19.7° (c=1, MeOH)
nu=max(KBr) 3280, 2950, 2920, 1655, 1640, and 1540 cm⁻¹

δH (250MHz, D6-DMSO) 0.72 (3H, d, J = 6Hz), 0.77 (3H, d, J = 7Hz), 0.95 (1H, m), 1.17 (3H, t, J = 7Hz), 1.29 (2H, m), 1.93 (2H, m), 2.49 (4H, m), 2.62 (1H, m), 2.82 (1H, dd, J = 14,10 Hz), 3.03 (1H, dd, J = 14,5 Hz), 3.19 (2H, m), 4.40 (1H, m), 7.22 (5H, m), 8.07 (2H, m), 8.75 (1H, s), and 10.39 (1H, s).

δC (62.9MHz, D6-DMSO) 174.0, 171.1, 167.7, 138.3, 129.2, 128.1, 126.3, 54.1, 40.8, 40.7, 38.8, 37.3, 35.8, 30.0, 25.3, 24.9, 23.5, 22.0, and 14.9.

Example 8


Using the procedure described in Example 1e [4-(N-Benzyloxyamino)-2R-isobutylsuccinyl]-L-phenylalanine (0.43g, 1.0 mmol) was coupled with O-methylethanolamine (90mg, 1.20mmol) then the product hydrogenated to give the title compound (92mg, 0.23 mmol 27%)

m.p. 151 - 153°C
nu_{max} (KBr) 3280, 2960, 1640, 1540, 1120, and 700 cm^{-1}

$\delta_H$ (250MHz, D$_6$-DMSO) 0.73 (3H, d, J = 6Hz), 0.78 (3H, d, J = 6Hz), 0.95 (1H, m), 1.29 (2H, m), 1.92 (2H, m), 2.61 (1H, m), 2.85 (1H, dd, J = 14, 10 Hz), 2.90 (1H, dd, J = 14, 4 Hz), 3.20 (1H, m), 3.27 (1H, m), 3.33 (3H, s), 4.43 (1H, m), 7.22 (5H, m), 7.91 (1H, m), and 8.08 (1H, d, J = 8Hz).

$\delta_C$ (62.9MHz, D$_6$-DMSO) 174.0, 171.2, 167.6, 138.3, 129.2, 128.1, 126.2, 70.5, 58.1, 54.0, 37.4, 35.8, 25.3, 23.4, and 21.9.

Analysis calculated for C$_{20}$H$_{31}$N$_3$O$_5$.H$_2$O

Required C 60.22 H 7.99 N 10.53

Found C 60.24 H 7.80 N 10.54

**Example 9**


![Chemical Structure]

Using the procedure described in Example 1e

[4-(N-Benzoylox amino)-2R-isobutylsuccinyl]-L-phenylalanine (0.43g, 1.0 mmol) was coupled with
N-acetyl-1,3-ethyldiamine (133mg, 1.30mmol) then the product hydrogenated to give the title compound (176mg, 0.42 mmol, 42%) m.p. 167 - 169°C

[α]D = -4.2° (c=1, MeOH)

νmax (KBr) 3280, 2930, 1640, 1540, and 700 cm⁻¹

δH (250MHz, D6-DMSO) 0.72 (3H, d, J= 6Hz), 0.77 (3H, d, J= 6Hz), 1.30 (2H, t, J= 10 Hz), 1.78 (3H, s), 2.06 (1H, m), 2.18 (1H, m), 2.87 (2H, m), 3.04 (2H, s), 3.13 (2H, q, J= 6 Hz), 3.36 (1H, m), 7.21 (5H, m), 7.78 (1H, s), 7.98 (1H, s), 8.08 (1H, d, J= 8Hz) and 8.77 (1H, s).

δC (62.9MHz, D6-DMSO) 174.8, 171.2, 169.4, 167.8, 138.3, 129.2, 128.1, 128.2, 54.2, 37.2, 35.8, 25.3, 23.4, 22.8 and 22.01.

Analysis calculated for C21H32N4O5.0.4H2O
Required C 58.97 H 7.73 N 13.10
Found C 59.07 H 7.60 N 12.90

Example 10

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide.
Using the procedure described in Example 1e
[4-(N-Benzylamino)-2R-isobutylsuccinyl]-L-phenyl-
alanine (0.43g, 1.0 mmol) was coupled with
1-(3-aminopropyl)-2-pyrrolidinone (180mg, 1.26mmol)
then the product hydrogenated to give the title
compound (280mg, 0.61 mmol, 61%)
m.p. 174 - 176°C

$\alpha_D = -8.7^\circ$ (c=1.35, MeOH)

$\nu_{max}(KBr)$ 3270, 3220, 2960, 1660, 1640, and 1525 cm$^{-1}$

$\delta_H$ (250MHz, D$_6$-DMSO) 0.72 (3H, d, J= 6Hz), 0.77 (3H,
d, J= 6Hz), 0.98 (1H, m), 1.33 (2H, m), 1.52 (2H, m),
1.87 - 2.06 (4H, m), 2.20 (2H, t, J= 8Hz), 2.62 (1H,m),
2.83 (1H, dd, J= 14.9 Hz), 2.99 (1H, t, J= 8 Hz), 3.10
(2H, t, J= 7 Hz), 3.28 (2H, m), 4.39 (1H, m), 7.22 (5H,
m), 7.91 (1H, m), 8.09'(1H, d, J= 8Hz), 8.80 (1H, bs),
and 10.4 (1H,bs).

$\delta_C$ (62.9MHz, D$_6$-DMSO) 174.0, 171.0, 167.7, 138.3,
129.2, 128.1, 126.2, 54.2, 46.6, 40.9, 40.6, 39.6,
38.7, 37.4, 36.5, 35.8, 30.6, 26.9, 25.3, 23.4, 22.1
and 17.7.
Analysis calculated for C_{24}H_{36}N_{4}O_{5}

Required  C  62.59 H  7.88 N 12.16 

Found      C  62.67 H  7.96 N 12.22

Example 11


\[
\begin{align*}
\text{CONHONa} \\
\text{CONHONa} \\
\text{CONHONa} \\
\text{CONHONa}
\end{align*}
\]

\[\text{[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenyl-alanine-N-(3-(1-pyrrolidone)propyl) amide}\]

0.109 mmol) was dissolved in methanol (20 ml) and sodium hydroxide solution (1.0 M, 0.11 ml) added to give a homogeneous solution. The methanol was removed under reduced pressure then the residual aqueous solution freeze dried to give the title compound (52 mg, 0.108 mmol, 99%).

\[\delta_{H} (250 MHz, D_{6}-\text{DMSO}) 0.66 (3H, d, J= 6 Hz), 0.75 (3H, d, J= 6 Hz), 0.94 (1H, m), 1.04 (2H, m), 1.56 (2H, m), 1.92 (3H, m), 2.08 (1H, dd, J= 14,8 Hz), 2.14 (2H, t, J= 8 Hz), 2.45 (1H, m), 2.83 (1H, dd, J= 14,10 Hz), 3.03 (2H, d, J= 6 Hz), 3.13 (4H, m), 3.23 - 3.48 (6H, m), 4.35 (1H, m), 7.20 (5H, m), 8.20 (1H, d, J= 8 Hz), and 8.53 (1H, s).\]
Example 12


\[
\begin{align*}
&\text{CONHOH} \\
&\text{OAc}
\end{align*}
\]

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-hydroxyethyl)-amide (Example 1e, 148mg, 0.32 mmol) was mixed with dimethylamino pyridine (40 mg, 0.33 mmol) in DCM at -30°C, then acetic anhydride (32 mg, 0.32 mmol) was added and the reaction stirred for 25 min. The mixture was partitioned between ethyl acetate and water, the organic layer separated and washed sequentially with sodium bicarbonate, citric acid and brine then dried over sodium sulphate. Purification by column chromatography (ethyl acetate as eluant) gave protected material (130mg) which was hydrogenated as before to give the title compound (62mg, 0.15mmol, 46%).

m.p. 136 - 137°C

\([\alpha]_D = -19.9^\circ\) (c=1.2, MeOH)

\(\text{nu}_{\text{max}}(\text{KBr})\) 3280, 2955, 1745, 1660, 1645, 1550 and 1235 cm\(^{-1}\)
\[ \delta_H \ (250\text{MHz}, \ \text{CDCl}_3/\text{D}_6-\text{DMSO}) \ 0.71 \ (3H, \ d, \ J= 6\text{Hz}), \ 0.75 \\
(3H, \ d, \ J= 6\text{Hz}), \ 0.99 \ (1H, \ m), \ 1.2 - 1.4 \ (2H, \ m), \ 1.96 \\
(1H, \ m + 3H, \ s), \ 2.11 \ (1H, \ dd, \ J= 14.8 \text{Hz}), \ 2.59 \\
(1H, m), \ 2.86 \ (1H, \ dd, \ J= 14.9 \text{Hz}), \ 3.06 \ (1H, \ dd, \ J= \\
14.5 \text{Hz}), \ 3.30 \ (2H, m), \ 3.95 \ (2H, t, \ J= 6 \text{Hz}), \ 4.44 \\
(1H, m), \ 7.16 \ (5H, m), \ and \ 8.00 \ (2H, m).
\]

\[ \delta_C \ (62.9\text{MHz}, \ \text{D}_6-\text{DMSO}) \ 174.1, \ 171.3, \ 170.1, \ 168.0, \\
138.0, \ 129.1, \ 127.9, \ 126.0, \ 78.8, \ 62.4, \ 41.0, \ 40.9, \\
37.8, \ 37.3, \ 35.8, \ 25.3, \ 23.1, \ 21.9 \ and \ 20.7.
\]

Analysis calculated for C_{21}H_{31}N_{3}O_{6} \cdot 0.4\text{H}_2\text{O}

Required C 58.84 H 7.48 N 9.80
Found C 58.91 H 7.33 N 9.55

**Example 13**

\[ [4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-
phenylalanine-N-(3-(2-pyrrolidone)propyl) amide. \]

\[ \text{(a) } 2S-\text{t}-\text{Butyl}(3,3\text{-di(benzylloxycarbonyl)}-2,5-
dimethyl)hexanoate \]

Benzyl (2-benzylloxycarbonyl-5-methyl) pentanoate
(100\text{\,g}, \ 0.29 \text{\,mol}) was dissolved in dry DMF (150 ml) and
cooled while potassium tert-butoxide (31.1\text{\,g}, \ 0.28
mol) was added portionwise over 10 minutes. This was
then stirred for a further 1 hour until the solid had dissolved. To the resultant mixture, cooled to -20 to -30°C, was added tert-butyl 2S-bromopropionate (60.6g, 0.29 mol) in dry DMF (50 ml) over about 30 minutes. The reaction mixture was left at -20°C for 3 days then 5°C for 1 day before working up by partitioning between ether and ammonium chloride solution. The aqueous layer was extracted three times with ether then the combined organic layers washed with brine and dried. Solvent removal gave the crude title compound (141.2g, 0.30 mol, 100%)

\[ [\alpha]_D = 33.0^\circ \text{ (c=1.00, MeOH)} \]

\[ \delta_H (250\text{MHz, CDCl}_3) 0.82 (6\text{H, d, J= 6 Hz}), 1.28 (3\text{H, t, J= 7 Hz}), 1.40 (9\text{H, s}), 1.46 (2\text{H, m}), 1.76 (1\text{H, m}), 1.92 (1\text{H, dd, J= 6,2 Hz}), 5.11 (4\text{H, m}), \text{ and } 7.27 (10\text{H, m}) \]

\[ \delta_C (62.9\text{MHz, CDCl}_3) 172.7, 170.3, 135.3, 128.2, 80.8, 66.9, 58.7, 45.2, 42.5, 27.8, 24.4, 23.9, 23.8, \text{ and } 14.3. \]

(b) 2S,3R tert-Butyl (3-carboxylic acid-2,5-dimethyl)-hexanoate

The crude material from Example 13a (141.2g, 0.30 mol) was taken up in ethanol (200 ml) and refluxed with activated charcoal (10g) for 1 hour to remove catalyst poisons. Cyclohexene (100 ml) and 10% palladium on charcoal (14g) was added and the mixture
refluxed for 2 hours. The catalyst was removed by filtration through celite and the solvent removed under reduced pressure.

The residual oil was taken up in xylene (200 ml) and refluxed for 30 minutes to effect decarboxylation. The solution was extracted with sodium carbonate solution (3 x 300 ml) this aqueous solution washed with ether then acidified to pH 5 with citric acid. The acidic solution was extracted with ethyl acetate (3 x 200 ml) then dried over sodium sulphate. Solvent removal then gave the crude title compound (53.2g, 0.22 mol, 73%)

\[ \alpha \]D = 8.0° (c=1.00, MeOH)

\[ \delta \]H (250MHz, CDCl3) 0.76 (6H, 2 x d, J= 6 Hz), 1.02 (3H, m), 1.28 (9H, s), 1.46 (2H, m), 2.42 (1H, m), and 2.58 (1H, m)

\[ \delta \]C (62.9MHz, CDCl3) 173.9, 128.7, 46.5, 43.0, 39.1, 27.8, 26.2, 23.5, 21.4, and 14.9.

(c) [4-(tert-Butyloxy)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine methyl ester

The crude acid from Example 13b (45.0g, 0.18 mol) was dissolved in DCM, then HOBT (24.9g, 0.18 mol) added. The solution was cooled and NMM (18g, 0.18 mol), phenylalanine methyl ester hydrochloride (36.1g, 0.17 mol) and DCC (38g, 0.18 mol) were added. This solution was stirred overnight, concentrated under vacuum then the precipitated DCU filtered off. The
The crude tert-butyl ester (80.6g, 0.20 mol) was dissolved in trifluoroacetic acid/water (95:5, 85 ml) and left at 4°C overnight. The solution was taken up in DCM, the aqueous layer re-extracted with DCM then the combined organic layers extracted with sodium bicarbonate (5 x 50 ml). The basic layer was acidified to pH 4 with citric acid then extracted with ethyl acetate. Drying and solvent removal gave the related acid (40.4g, 0.115 mol, 69%).

The crude acid (40.4g, 115mmol) was dissolved in DCM/DMF (4:1, 500ml), then HOBT (17.18g 127mol) and DCC (26.1g, 127mmol) were added and the mixture stirred at room temperature until tlc indicated complete conversion to the activated ester (about 10 minutes). To this solution containing the active ester was added benzylhydroxylamine (15.6g, 127mmol). After stirring at room temperature overnight DCM was removed under vacuum, the residue taken up in ethyl acetate then precipitated DCU removed by filtration. The solution was washed with citric acid (2x250ml), 10% sodium bicarbonate solution (2x250ml)
and brine (250ml) then finally dried over sodium
sulphate. The solvent was removed under reduced
pressure to give an oil (45.6g) which was purified by
recrystallisation from ethanol and DIPE (7.66g, 17mmol,
15%).

δₓ (250MHz, CDCl₃) 0.47 (3H, d, J= 7 Hz), 0.74 (3H, d,
J= 6 Hz), 0.83 (3H, d, J= 6 Hz), 1.35 (2H, m), 1.94
(1H, dd, J= 7,11 Hz), 2.38 (1H, m), 2.83 (1H, dd, J=
14,11 Hz), 3.06 (1H, dd, J= 5,14 Hz), 3.29 (3H, s),
3.62 (3H, s), 4.58 (1H, m), 4.77 (2H, s), 7.20 (5H, m),
7.38 (5H, s), and 8.49 (1H, d, J= 8 Hz).

(e)[4-(N-Benzyloxyamino)-2R-isobutyl-3S-methyl-
succinyl]-L-phenylalanine methyl ester (7.66g,
17mmol) was dissolved in methanol (120ml) and sodium
hydroxide solution (1.0 M, 20.3ml, 20.3mmol) was added
with stirring at room temperature. When the reaction
was complete, as judged from tlc, the methanol was
removed by evaporation the residue extracted with ether
to remove starting material (2.1g, 4.6 mmol, 21%
recovered). The aqueous phase was acidified to pH4
with citric acid and extracted with ethyl acetate to
give the title compound (5.88g, 13.3mmol, 79%).

δₓ (250MHz, CDCl₃) 0.47 (3H, d, J= 7 Hz), 0.74 (3H, d,
J= 6 Hz), 0.83 (3H, d, J= 6 Hz), 1.35 (2H, m), 1.94
(1H, dd, J= 7,11 Hz), 2.38 (1H, m), 2.83 (1H, dd, J=
1 14.11 Hz), 3.06 (1H, dd, J = 5.14 Hz), 3.29 (3H, s),
2 3.62 (3H, s), 4.58 (1H, m), 4.77 (2H, s), 7.20 (5H, m),
3 7.38 (5H, s), and 8.49 (1H, d, J = 8 Hz).
4
5 (f) [4-(N-Hydroxyamino)-2R-isobutyl-3S-methyl-
6 succinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl)
7 amide.
8
9 [4-(N-Benzylamino)-2R-isobutyl-3S-methylsuccinyl]-L-
10 phenyl alanine (400 mg, 0.9 mmol), HOBT (134 mg, 1.0
11 mmol) and NMM (102 mg, 1.0 mmol) were dissolved in
12 DCM/DMF (4:1, 10 ml) and cooled in ice.
13 l-(3-Aminopropyl)-2-pyrrolidinone (142 mg, 1.0 mmol)
14 was added together with WSCDI (192 mg, 1.0 mmol).
15 After 2h at room temperature the reaction mixture was
16 diluted with ethyl acetate then washed with sodium
17 bicarbonate solution and brine, then dried over sodium
18 sulphate. Solvent removal under reduced pressure gave
19 the crude benzyl hydroxamate which was recrystallised
20 from ethyl acetate/hexane (385 mg, 0.68 mmol)
21
22 The material from above was dissolved in
23 cyclohexene/ethanol (10% solution, 20 ml), 10%
24 palladium on charcoal (50 mg) was added then the
25 mixture refluxed until starting material had
26 dissapeared by tlc (ca. 30 minutes). The catalyst was
27 removed by filtration, and the solvent removed under
28 reduced pressure to leave a solid which could be
29 recrystallised from ethyl acetate/ethanol. The
30 required product (243 mg, 0.51 mmol, 76%) was
31 collected by filtration.
32
33 m.p. 198 - 200°C
[α]D = 73.0° (c=1.00, MeOH)

νmax(KBr) 3380, 2960, 1635, 1345, 1030, and 715 cm⁻¹

δH (250MHz, D6-DMSO) 0.44 (3H, d, J= 7Hz, CHCH3), 0.72
(3H, d, J= 6Hz, CH(CH3)2), 0.80 (3H, d, J= 6Hz,
CH(CH3)2), 1.32 (2H, m), 1.53 (2H, q, J= 7 Hz), 1.92
(4H, m), 2.21 (2H, t, J= 8 Hz), 2.37 (1H, m), 2.79 (1H,
m), 2.93 (1H, d, J= 5 Hz), 3.01 (2H,m), 3.13 (2H, t, J= 7Hz), 3.32 (6H, m), 4.54 (1H, m), 7.25 (5H, m), 7.80
(1H, t, J= 7 Hz), 8.20 (1H, d, J= 8Hz, NH), 8.69 (1H,
s), and 10.36 (1H, s).

δC (62.9MHz, D6-DMSO) 174.0, 173.9, 171.4, 171.2,
138.2, 129.3, 128.0, 126.3, 54.6, 47.0, 46.7, 36.3,

Analysis calculated for C25H38N4O5·0.5H2O
Required C 62.20 H 7.93 N 11.50
Found C 63.27 H 8.07 N 11.81

Example 14

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-
L-phenylalanine-N-methyl-N-(2-hydroxyethyl) amide.

[Image of the molecule structure]
Using the procedure described in Example 13f

[4-(N-Benzoylamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine (0.4g, 0.91mmol) was coupled with N-methylethanolamine (75mg, 1.00mmol) then the product hydrogenated to give the title compound (100mg, 0.25 mmol, 27%)

m.p. 182 - 183°C

[α]D = -27.00° (c=0.25, MeOH)

ν max (KBr) 3400, 3240, 2960, 1660, and 1545 cm⁻¹

δ H (250MHz, D 6 -DMSO, mixture of rotamers) 0.46 + 0.54

(3H, d, J= 6Hz, CHCH 3), 0.72 + 0.79 (6H, m, CH(CH 3) 2),
1.3 (2H, m), 2.0 (1H, m), 2.4 (1H, m), 2.81 + 3.03

(3H, s, N(CH 3)), 2.8 - 3.9 (8H, m), 5.0 (1H, m), 7.27

(5H, m), 8.35 (1H, d, J= 8Hz, NH), and 8.73 (1H, m).

δ C (62.9MHz, D 6 -DMSO, mixture of rotamers), 173.3,

173.2, 171.6, 171.4, 171.0, 138.3, 138.0, 129.4,

128.1, 128.0, 126.4, 126.3, 58.8, 58.5, 51.4, 50.2,

50.1, 49.9, 46.7, 40.1, 37.4, 37.1, 36.2, 33.9, 25.5,


Analysis calculated for C 21 H 33 N 3 O 5 ·H 2 O

Required C 59.28 H 8.29 N 9.87

Found C 59.30 H 7.91 N 9.94

Example 15

Using the procedure described in Example 13f
4-(N-Benzylamino)-2R-isobutyl-3S-methylsuccinyl-L-phenylalanine (0.4g, 0.91mmol) was coupled with ethanolamine (61mg, 1.00mmol) then the product hydrogenated to give the title compound (51mg, 0.13 mmol, 14%)
m.p. 208 - 210°C
[a]D = 24.0° (c=0.30, MeOH)
νmax(KBr) 3280, 2960, 1635, 1540, 1450, and 1370 cm⁻¹
δH (250MHz, D6-DMSO) 0.39 (3H, d, J= 6Hz, CH(CH3)J, 0.73 (3H, d, J= 6Hz, CH(CH3)2), 0.80 (3H, d, J= 6Hz, CH(CH3)2), 1.33 (2H, t, J= 10 Hz), 1.94 (1H, t, J= 8Hz), 2.34 (1H, t, J= 10 Hz), 2.77 (2H, t, J= 12 Hz), 3.01 (2H, dd, J= 11.3 Hz), 3.13 (2H, q, J= 6Hz), 4.61 (1H, m), 4.66 (1H,m), 7.20 (5H, m), 7.73 (1H, s), 8.18 (1H, d, J= 8Hz, NH), and 8.69 (1H, s).
δC (62.9MHz, D6-DMSO) 173.5, 171.4, 138.3, 128.1, 126.3, 59.9, 54.2, 46.8, 41.6, 37.4, 25.4, 24.3, 21.7, and 16.1.
Analysis calculated for C20H31N3O5.0.5H2O.
1. Required C 59.68 H 8.01 N 10.44
2. Found C 59.38 H 7.71 N 10.27

Example 16

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalaninyl-D-prolinol.

Using the procedure described in example 13f [4-(N-Benzylxamino)-2R-isobutyl-3-methylsuccinyl]-L-phenylalanine (0.41g, 1.00mmol) was coupled with S-pyrrolidine methanol (130mg, 1.29mmol) then the product hydrogenated to give the title compound (180mg, 0.41 mmol, 41%)

\( \text{nu}_{\text{max}}(\text{KBr}) \) 3310, 2900, 1630, 1540, and 1440 cm\(^{-1}\)

\( \delta_H (250\text{MHz, } D_6-\text{DMSO}) \) 0.58 (3H, d, \( J = 7\text{Hz, } CH_3CH \)), 0.78 (6H, 2xd, \( J = 7\text{Hz, } CH(CH_3)_2 \)), 0.82 (1H, m, CHMe\(_2\)), 1.38 (2H, m,CHCH\(_2\)CH), 1.82 (4HH, m, CH\(_2\)CH\(_2\)), 2.02 (1H, m, CHCONH), 2.44 (1H, m, CHCONHOH), 3.00 (4H, m, CH\(_2\)Ph + CONHCH\(_2\)) 3.42 (1H, m, CONH), 3.62 (3H m, CHCH\(_2\)Ph + CH\(_2\)OH), 4.70 (1H, m, NHCHCO), and 7.20 (5H, m, Ph).
Example 17

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-
L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide
sodium salt.

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-
L-phenylalanine-N-(3-(1-pyrrolidone)propyl) amide
(50mg, 0.1mmol) was dissolved in methanol (1ml) and
sodium hydroxide solution (1.0M, 2.0ml) added to give
a homogeneous solution. The methanol was removed under
reduced pressure then the residual aqueous solution
freeze dried to give the title compound (53mg, 0.1mmol,
100%).

δH (250MHz, D6-DMSO) 0.44 (3H, d, J= 7Hz, CHCH3), 0.72
(3H, d, J= 6Hz, CH(CH3)2), 0.79 (3H, d, J= 6Hz,
CH(CH3)2), 1.32 (2H, m), 1.53 (2H, q, J= 7 Hz), 1.92
(4H, m), 2.21 (2H, t, J= 8 Hz), 2.37 (1H, m), 2.79 (1H,
m), 2.93 (1H, d, J= 5 Hz), 3.01 (2H, m), 3.13 (2H, t,
J= 7 Hz), 3.26 - 3.43 (6H, m), 4.54 (1H, m), 7.22 (5H,
m), 7.85 (1H, t, J= 7 Hz), and 8.28 (1H, d, J= 8 Hz,
NH).

δC (62.9MHz, D6-DMSO) 174.0, 173.4, 170.8, 129.2,
127.7, 126.0, 54.6, 47.0, 46.7, 37.7, 36.3, 30.7,
Example 18

Collagenase inhibition activity

The potency of compounds of general formula I to act as inhibitors of collagenase (a metalloprotease involved in tissue degradation) was determined by the procedure of Cawston and Barrett, (Anal. Biochem., 99, 340-345, 1979), hereby incorporated by reference, whereby a 1mM solution of the inhibitor being tested or dilutions thereof was incubated at 37°C for 16 hours with collagen and collagenase (buffered with 25mM Hepes, pH 7.5 containing 5mM CaCl₂, 0.05% Brij 35 and 0.02% NaN₃). The collagen was acetylated ¹⁴C collagen prepared by the method of Cawston and Murphy (Methods in Enzymology, 80, 711, 1981), hereby incorporated by reference. The samples were centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of 1 mM inhibitor, or a dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported below as that inhibitor concentration effecting 50% inhibition of the collagenase (IC₅₀).

<table>
<thead>
<tr>
<th>Compound of Example No.</th>
<th>IC₅₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>200 nM</td>
</tr>
<tr>
<td>7</td>
<td>20 nM</td>
</tr>
<tr>
<td>9</td>
<td>90 nM</td>
</tr>
</tbody>
</table>

Examples of unit dosage compositions are as follows:
Example 19

Capsules:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Per Capsule</th>
<th>Capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Active ingredient</td>
<td>40.0 mg</td>
<td>400 g</td>
</tr>
<tr>
<td>(Cpd of Formula I)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Lactose</td>
<td>150.0 mg</td>
<td>1500 g</td>
</tr>
<tr>
<td>3. Magnesium stearate</td>
<td>4.0 mg</td>
<td>40 g</td>
</tr>
<tr>
<td></td>
<td>194.0 mg</td>
<td>1940 g</td>
</tr>
</tbody>
</table>

Procedure for capsules:

Step 1. Blend ingredients No. 1 and No. 2 in a suitable blender.

Step 2. Pass blend from Step 1 through a No. 30 mesh (0.59 mm) screen.

Step 3. Place screened blend from Step 2 in a suitable blender with ingredient No. 3 and blend until the mixture is lubricated.

Step 4. Fill into No. 1 hard gelatin capsule shells on a capsule machine.
Example 20

Tablets:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Per Tablet</th>
<th>Per 10,000 Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Active ingredient (Cpd of Form. I)</td>
<td>40.0 mg</td>
<td>400 g</td>
</tr>
<tr>
<td>2. Corn Starch</td>
<td>20.0 mg</td>
<td>200 g</td>
</tr>
<tr>
<td>3. Alginic acid</td>
<td>20.0 mg</td>
<td>200 g</td>
</tr>
<tr>
<td>4. Sodium alginate</td>
<td>20.0 mg</td>
<td>200 g</td>
</tr>
<tr>
<td>5. Magnesium stearate</td>
<td>1.3 mg</td>
<td>13 g</td>
</tr>
</tbody>
</table>

Procedure for tablets:

Step 1. Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender.

Step 2. Add sufficient water portionwise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.

Step 3. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38mm) screen.

Step 4. The wet granules are then dried in an oven at 140°F (60°C) until dry.

Step 5. The dry granules are lubricated with ingredient No. 5.

Step 6. The lubricated granules are compressed on a suitable tablet press.
Example 21

Intramuscular Injection:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Per ml.</th>
<th>Per liter</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Formula I compound</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active ingredient</td>
<td>10.0 mg</td>
<td>10 g</td>
</tr>
<tr>
<td>2. Istonic buffer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>solution pH 4.0.</td>
<td>q.s.</td>
<td>g.s.</td>
</tr>
</tbody>
</table>

Procedure:

Step 1. Dissolve the active ingredient in the buffer solution.
Step 2. Aseptically filter the solution from Step 1.
Step 3. The sterile solution is now aseptically filled into sterile ampoules.
Step 4. The ampoules are sealed under aseptic conditions.

Example 22

Suppositories:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Per Supp.</th>
<th>1,000 Supp</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Formula I compound</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active ingredient</td>
<td>40.0 mg</td>
<td>40 g</td>
</tr>
<tr>
<td>2. Polyethylene Glycol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td>1350.0 mg</td>
<td>1,350 g</td>
</tr>
<tr>
<td>3. Polyethylene Glycol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4000</td>
<td>450.0 mg</td>
<td>450 g</td>
</tr>
<tr>
<td></td>
<td>1840.0 mg</td>
<td>1,840 g</td>
</tr>
</tbody>
</table>

Procedure:

Step 1. Melt ingredient No. 2 and No. 3 together and
1. stir until uniform.
2. Step 2. Dissolve ingredient No. 1 in the molten mass from Step 1 and stir until uniform.
3. Step 3. Pour the molten mass from Step 2 into suppository moulds and chill.
4. Step 4. Remove the suppositories from moulds and wrap.

Example 23

Eye Ointment

An appropriate amount of a compound of general formula I is formulated into an eye ointment base having the following composition:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid paraffin</td>
<td>10%</td>
</tr>
<tr>
<td>Wool fat</td>
<td>10%</td>
</tr>
<tr>
<td>Yellow soft paraffin</td>
<td>80%</td>
</tr>
</tbody>
</table>

Example 24

Topical skin ointment

An appropriate amount of a compound of general formula I is formulated into a topical skin ointment base having the following composition:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emulsifying wax</td>
<td>30%</td>
</tr>
<tr>
<td>White soft paraffin</td>
<td>50%</td>
</tr>
<tr>
<td>Liquid paraffin</td>
<td>20%</td>
</tr>
</tbody>
</table>
1. A compound of general formula I:

\[
\begin{align*}
&\text{HO-}N-\text{C} = \text{O} \quad R^2 \\
&\text{N-}C\text{=O} \quad R^3 \\
&\text{N-}C\text{=O} \quad R^4 \\
&\text{S-R}^5 
\end{align*}
\]

wherein:

- \( R^1 \) represents a hydrogen atom or a \( \text{C}_1\text{-C}_6 \) alkyl, \( \text{C}_1\text{-C}_6 \) alkenyl, phenyl, phenyl(\( \text{C}_1\text{-C}_6 \)alkyl, \( \text{C}_1\text{-C}_6 \) alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl(\( \text{C}_1\text{-C}_6 \)alkylthiomethyl or heterocyclylthiomethyl group; or \( R^1 \) represents \(-S-R^X\)
  - wherein \( R^X \) represents a group

- \( R^2 \) represents a hydrogen atom or a \( \text{C}_1\text{-C}_6 \) alkyl, \( \text{C}_1\text{-C}_6 \) alkenyl, phenyl(\( \text{C}_1\text{-C}_6 \)alkyl, cycloalkyl(\( \text{C}_1\text{-C}_6 \)alkyl, or cycloalkenyl(\( \text{C}_1\text{-C}_6 \)alkyl;

- \( R^3 \) represents an amino acid side chain or a \( \text{C}_1\text{-C}_6 \) alkyl, benzyl, (\( \text{C}_1\text{-C}_6 \)alkoxybenzyl, benzyloxy- (\( \text{C}_1\text{-C}_6 \)alkyl or benzyloxybenzyl group;
1. $R^4$ represents a hydrogen atom or a methyl group;
2. $R^5$ represents a group $(\text{CH}_2)_nA$;
3. or $R^4$ and $R^5$ together represent a group

![Chemical Structure](image)

4. $Q$ represents $\text{CH}_2$ or $\text{CO}$;
5. $m$ is an integer from 1 to 3;
6. $n$ is an integer from 1 to 6; and
7. $A$ represents a hydroxy, $(\text{C}_1-\text{C}_6)$alkoxy, $(\text{C}_2-\text{C}_7)$acyloxy, $(\text{C}_1-\text{C}_6)$alkylthio, phenylthio, $(\text{C}_2-\text{C}_7)$acylamino or N-pyrrolidone group
8. or a salt and/or N-oxide and/or (where the compound is a thio-compound) a sulphoxide or sulphone thereof.

2. A compound as claimed in claim 1, in which the chiral centre adjacent the substituent $R^3$ has S stereochemistry.

3. A compound as claimed in Claim 1 or 2, wherein $R^1$ represents a hydrogen atom or a $\text{C}_1-\text{C}_4$ alkyl, phenylthiomethyl or heterocyclylthiomethyl group.

4. A compound as claimed in Claim 1, 2 or 3, wherein $R^2$ represents a $\text{C}_3-\text{C}_6$ alkyl group.
5. A compound as claimed in any one of Claims 1 to 4, wherein \( R^3 \) represents a benzyl, 4-(C\( _1-C_6 \))alkoxyphenylmethyl or benzyloxy benzyl group.

6. A compound as claimed in any one of Claims 1 to 5, wherein \( R^4 \) represents a hydrogen atom or \( R^4 \) and \( R^5 \) together represent a group

\[
\text{CH}_2\text{OH}
\]

7. A compound as claimed in any one of Claims 1 to 6, wherein \( n \) has the value 1, 2 or 3.

8. A compound as claimed in any one of Claims 1 to 7, wherein \( R^5 \) represents a pyrrolidone, hydroxy, methoxy or thioethyl group.

9. [4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-hydroxyethyl)-amide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalaninyl-proline;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-hydroxyethyl)-N-methylamide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalaninyl-D-prolinol;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalaninyl-L-prolinol;
[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(5-N-methyl-pentylcarboxamide) amide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-ethyl thioethyl) amide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-methoxyethyl) amide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-N-acetylethyl) amide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide sodium salt;

[4-(N-Hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine-N-(2-acetoxyethyl) amide;

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide;

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-methyl-N-(2-hydroxyethyl) amide;
[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(2-hydroxyethyl) amide;

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalaninyl-D-prolinol; or

[4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl) amide sodium salt;

or a free base, free acid or salt thereof.

10. [4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl)amide or a salt thereof.

11. [4-(N-Hydroxyamino)-2R-isobutyl-3S-methylsuccinyl]-L-phenylalanine-N-(3-(2-pyrrolidone)propyl)amide or a salt thereof.

12. A compound as claimed in any one of claims 1 to 11 for use in human or veterinary medicine.

13. The use of a compound as claimed in any one of claims 1 to 11 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.
14. A pharmaceutical or veterinary formulation
comprising a compound as claimed in any one of claims 1
to 11 and a pharmaceutically and/or veterinarily
acceptable carrier.

15. A process for preparing a compound of general
formula I as defined in claim 1, the process
comprising:

(a) deprotecting a compound of general formula III

\[
\text{NH} \quad \text{R}^1 \text{R}^2 \text{R}^3 \text{R}^4 \text{R}^5
\]

wherein:

\[ R^1, R^2, R^3, R^4 \text{ and } R^5 \text{ are as defined in general }
\]

formula I and Z represents a protective group; or

(b) reacting a compound of general formula IV

\[
\text{HO} \quad \text{R}^1 \text{R}^2 \text{R}^3 \text{R}^4 \text{R}^5
\]

wherein:

\[ R^1, R^2, R^3, R^4 \text{ and } R^5 \text{ are as defined in general }
\]

formula I, with the proviso that \( R^1 \) represents a
hydrogen atom,

with hydroxylamine or a salt thereof; and
(c) optionally after step (a) or step (b) converting a compound of general formula I into another compound of general formula I.

16. A compound of general formula III

![Chemical Structure of III]

wherein:

R₁, R₂, R³, R⁴ and R⁵ are as defined in general formula I and Z represents a protective group.

17. A compound of general formula IV

![Chemical Structure of IV]

wherein:

R₁, R₂, R³, R⁴ and R⁵ are as defined in general formula I, with the proviso that R¹ represents a hydrogen atom.